Mechanistic Studies S2
(ρ ≥ 0 expected) α-Elimination. In addition to the absence of H/D migration products with 8-d 1 (Scheme 4), the α-elimination mechanism can not explain the formation of the bisarylation products. During the second arylation step, there is no α-H available for the elimination in 15 (Scheme S3).
Scheme S3.
Electrophilic Palladation. In addition to the arylation of 8, arylation of 17 also occurs preferentially at the less electron-rich 5-position (Scheme S4). The regioselectivity is opposite to the electrophilic formylation of 17.
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Scheme S4.
Computational Studies
The activation barriers for the acetate ligand-assisted C-H insertion of the cis-and trans-PdL 2 X 2 complex (Scheme S5, Table S2 ) were evaluated. All the computations were performed on Jaguar 6.5 suite S1 using the B3LYP functional and LACVP**++ basis set.
S , 2 3 All stationary points were subjected to frequency analysis and characterized as a minimum (no imaginary frequencies) or as a saddle point (single imaginary frequency) on the potential energy surface. Transition states were verified by imaginary frequency animation with desired vibrational modes. The single-point energy and solvation energy (DMSO, dielectric constant: 47.240, probe radius: 2.41 Å) calculations were then performed on the gas-phase optimized geometries. The solvation was treated with a self-consistent reaction field (SCRF) method, using its own Poisson-Boltzmann solver.
S , 4 5 Zero-point-energy (ZPE) and entropy corrections were derived using unscaled frequencies. Thermodynamic properties were calculated assuming ideal gas at 298.15 K. The resulting activation barrier for the cis-PdL 2 X 2 complex (ΔH ‡ DMSO,298.15K = 17.9 kcal/mol) is comparable to the reported activation barriers for the Wacker oxidation (ΔH ‡ H2O,0K = 12.5-18.8 kcal/mol) calculated by the same method. C NMR spectra are reported in ppm (δ) relative to residue protium in the solvent (CDCl 3 : δ 7.26, 77.23 ppm; DMSO-d 6 : δ 2.50, 39.51 ppm) and the multiplicities are presented as follows: s = singlet, d = doublet, t = triplet, m = multiplet. Infrared spectra were recorded on a Perkin-Elmer 1000 series FTIR. Mass spectra were acquired on a Shimadzu 2010 LC-MS using the indicated ionization method.
Materials. Commercial solvents and reagents were used as received except that dimethyl sulfoxide was degassed by freeze-pump-thaw cycles, and 2,2,2-trichloroethanol was treated with calcium sulfate and sodium bicarbonate followed by distillation. Imidazolinone (1) S7 and 2-(3-bromoallyl)isoindoline-1,3-dione (11) S , 8 9 are both commercially available and can be easily prepared in large scales.
S9
General procedure for the C-arylation of imidazolinone (1). Palladium(II) acetate (6.7 mg, 0.0298 mmol, 0.05 equiv), imidazolinone (1) (50 mg, 0.595 mmol, 1.0 equiv) and sodium acetate trihydrate (242.8 mg, 1.78 mmol, 3.0 equiv) were weighed and added to an argon-filled 16 mL vial. Aryl iodide (0.892 mmol, 1.5 equiv) and degassed dimethyl sulfoxide (2.5 mL) were then added and the vial was purged with argon for 1 min. After stirring in dark at 80 °C with the time indicated in Table 1 , the solvent was removed. The crude residue was dissolved in methanol and dry-loaded onto a RP-18 silica gel column for chromatography purification. For arylation using aryl bromides, palladium(II) acetate (13.4 mg, 0.0595 mmol, 0.1 equiv), imidazolinone (1) (50 mg, 0.595 mmol, 1.0 equiv), aryl bromide (0.892 mmol, 1.5 equiv, if solid) and sodium acetate trihydrate (242.8 mg, 1.78 mmol, 3.0 equiv) were added to a 10 mL round-bottom flask and vigorously degassed. Degassed DMSO (2.5 mL) and aryl bromide (0.892 mmol, 1.5 equiv, if liquid) were then added. The reaction was stirred in dark at 80°C with the time indicated in Table 1 and S1.
4-Phenyl-1H-imidazol-2(3H)-one. According to the general procedure using iodobenzene and purified with RP-18 silica gel column chromatography (0→80% methanol-water): R f = 0.30 (10% methanol-methylene chloride); FTIR (neat, cm -1 ) 1704, 1644, 1616, 1454, 1130, 938, 772, 730 
4-(2-(Hydroxymethyl)phenyl)-1H-imidazol-2(3H)-one.
According to the general procedure using 2-iodobenzyl alcohol and purified with RP-18 silica gel column chromatography (0→80% methanol-water): R f = 0. 
4-(3-(Hydroxymethyl)phenyl)-1H-imidazol-2(3H)-one.
According to the general procedure using 3-iodobenzyl alcohol and purified with RP-18 silica gel column chromatography (0→80% methanol-water): R f = 0.09 (10% methanolmethylene chloride); FTIR (neat, cm .5, 137.9, 129.4, 127.5, 126.3, 123.8, 122.6, 117.1, 110.9 4, 160.4, 142.7, 135.9, 134.4, 132.5, 130.8, 128.0, 126.5, 32.3 
1,3-Dimethyl-4-phenyl-1H-imidazol-2(3H)-one (6).
According to the general procedure using 5 and iodobenzene and purified with silica gel (Davisil 633) column chromatography: R f = 0.11 (100% ethyl acetate); FTIR (neat, cm -1 ) 2925, 1715, 1681, 1467, 1398, 1291, 1183, 1041, 1016, 855, 787, 766, 728; 1 H NMR (400 MHz, C δ 7.40-7.29 (m, 5H), 6.21 (s, 1H), 3.30 (s, 3H), 3.27 (s, 3H); Difluoromethyl-3-methyl-1H-imidazol-2-one (8) . A modified procedure was used to form the imidazol-2-one preferentially under aerobic conditions. S10 A mixture of N-methyl-imidazole (328.5 mg, 4.0 mmol, 1.0 equiv) and sodium fluoride (16.8 mg, 0.4 mmol, 0.1 equiv) in anhydrous 1,2-dimethoxyethane (20 mL) was stirred at 85 °C for 20 minutes before trimethylsilylfluorosulfonyldifluoroacetate (4.00 g, 16.0 mmol, 4.0 equiv) was added dropwise. After stirring the reaction at 85 °C for 16 h, the solvent was removed and the residue was purified by silica gel flash chromatography to give 8 as yellow oil ( . To a solution of 2,5-diiodo-1-methylimidazole S11 (1.00 g, 3.0 mmol, 1.0 equiv) in tetrahydrofuran-ether (1:1, 10 mL) at -78 °C was added tert-butyllithium (1.7 M in pentane, 7.06 mL, 12.0 mmol, 4.0 equiv) dropwise along the flask wall. After stirring for 5 min, deuterium oxide (1.0 mL) was added. The aqueous phase was removed and the organic phase was concentrated. The residue was re-dissolved in methylene chloride, dried with anhydrous sodium sulfate, filtrated and concentrated to give the 2,5-dideutero-1-methylimidazole as colorless oil, which was converted to 8-d 1 as described above (93% D at C-4 and 9% D at C-5 by NMR).
1-
1-Difluoromethyl-3-methyl-4-phenyl-1H-imidazol-2(3H)-one (9) and 1-difluoromethyl-3-methyl-5-phenyl-1H-imidazol-2(3H)-one (10). According to the general procedure, imidazolinone 8 was reacted with iodobenzene at 23 °C for 48 h to give 9 and 10 (6:1) as determined by NMR with 10 s recycle delay. Imidazolinone 9 and 10 can be separated by PTLC (250 μm Silica Gel 60 F 254 ). 9: R f = 0.44 (50% ethyl acetate-hexanes); FT-IR (neat, cm -1 ) 1726 , 1710 , 1459 , 1396 , 1238 , 1180 , 1172 , 1112 , 1022 3, 129.3, 129.2, 128.5, 128.4, 128.1, 107.7 1709, 1437, 1453, 1401, 1355, 1262, 1121, 1047, 1006, 891, 804, 762; 1 H NMR (400 MHz, CDCl 3 ) δ 7.48-7.37 (m, 5H), 7.20 (t, J = 59.2 Hz, 1H), 6.24 (s, 1H), 3.31(s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 152. 6, 128.8, 128.7, 128.6, 122.1, 112.5, 109.4 (t, J = 245.8 
1-(4-Methoxybenzyl)-3-(4-nitrobenzyl)-4-phenyl-1H-imidazol-2(3H)-one (15) and 1-(4-methoxybenzyl)-3-(4-nitrobenzyl)-5-phenyl-1H-imidazol-2(3H)-one (16).
According to the general procedure using imidazolinone 13 and iodobenzene, 14 and 15 were obtained as yellow oil from PTLC (250 μm Silica Gel 60 F 254 ) in 1.8:1 ratio (ca. 20% conversion by 1 H NMR). 14: R f = 0.35 (50% ethyl acetate-hexanes); FT-IR (neat, cm -1 ) 1682 , 1608 , 1514 , 1453 , 1409 , 1344 , 1247 , 1176 , 1110 , 1032 1 H NMR (400 MHz, CDCl 3 ) δ 8.11 (d, J = 8.8 Hz, 2H), 7H), 2H), 6.89 (d, J = 8.8 Hz, 2H); 13 C NMR (75 MHz, CDCl 3 ) δ 159. 6, 147.5, 145.4, 129.8, 129.3, 129.1, 129.0, 128.8, 128.7, 128.6, 128.3, 128.1, 127.8, 124.1, 114.5, 108.7, 55.6, 47.2, 45 1682, 1609, 1514, 1453, 1410, 1284, 1176, 1108, 1032, 846, 801, 767, 733; 1 H NMR (400 MHz, CDCl 3 ) δ 8.21 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 3H), 2H) 154.2, 147.8, 144.6, 129.9, 129.4, 128.9, 128.8, 128.7, 128.6, 126.0, 124.3, 114.1, 107.9, 55.5, 46.9, 45.3 (E,Z)-2-(3-bromoallyl)isoindoline-1,3-dione (11). S8 1,3-Dibromo-1-propene (5.149 g, 25.76 mmol, 1.0 equiv) was added dropwise to a suspension of phthalimide potassium salt (4.77 g, 25.76 mmol, 1.0 equiv) and tetrabutylammonium bromide (415.2 mg, 1.29 mmol, 0.05 equiv) in anhydrous N,N-dimethylformamide (70 mL) at 23 °C. S9 After stirring for 16 h, the solvent was removed and the residue was dissolved in methylene chloride (300 mL), washed with water (200 mL×3), dried with anhydrous sodium sulfate, concentrated and recrystallized from ethyl acetate-hexanes to give 11 as white crystalline solid (6.256 g, 91% trans:cis = 2:3): R f = 0.29 (20% ethyl acetate-hexane); FTIR (neat, cm -1 ) 1771, 1712, 1467, 1426, 1391, 1350, 1290, 1188, 1110 N-(3-(2,3-dihydro-2-oxo-1H-imidazol-4-yl) propyl)-1H-pyrrole-2-carboxamide (13). Imidazol-2-one (1) (840.8 mg, 10 mmol, 10 equiv), vinyl bromide 11 (266.1 mg, 1.0 mmol, 1.0 equiv) and sodium acetate trihydrate (480.2 mg, 3.0 mmol, 3 equiv) were vacuum-dried and filled with argon for 3 times before degassed dimethyl sulfoxide (9 mL) was introduced. After stirring at 80 °C in dark for 10 min, a solution of palladium acetate (44.9 mg, 0.2 mmol, 0.2 equiv) in degassed dimethyl sulfoxide (1.0 mL) was quickly added. The reaction was stirred at 80 °C in dark for 2 h and quenched by pouring into water (100 mL). The mixture was filtered through a short pad of RP-C18 silica gel and washed with 10% methanol-H 2 O (100 mL) followed by N,N-dimethylformamide (100-120 mL). The N,N-dimethylformamide wash portion was collected and used directly for the next step. The N,N-dimethylformamide portion from the above step was dilute with methanol (120 mL) and was hydrogenated under hydrogen (1 atm) at room temperature for 12 h. The solution was filtered and the filtrate was concentrated to dryness. The solid was washed with methylene chloride (3 mL×3), and concentrated to give 2-(3-(2,3-dihydro-2-oxo-1H-imidazol-5-yl)propyl)isoindoline-1,3-dione: R f = 0.43 (10% methanol-methylene chloride); FTIR (neat, cm -1 ) 3401, 3307, 1996, 1766, 1710, 1631, 1552, 1402 The 2-(3-(2,3-dihydro-2-oxo-1H-imidazol-5-yl)propyl)isoindoline-1,3-dione obtained above was suspended in methanol (200 mL) and heated at 75 °C for 30 min. The remaining palladium was filtered off to afford a clear orange solution. Anhydrous hydrazine (1.28 mL, 40 mmol, → 0.2 M in methanol) was then added dropwise to this solution at 75 °C. After heating at 75 °C for 1 h, the yellow solution was concentrated, azeotroped with ethanol (20 mL×2) and dried under vacuum for 2 h. The resulting solid was then dissolved in deionized water (25 mL), and stirred with activated Dianion WA30 resin (10 mL) until the aqueous phase became clear and colorless. The mixture was filtered and the resin was washed with deionized water (5 mL×2). The aqueous solution was concentrated, azeotroped with toluene (5 mL×3) and dried under vacuum for 6 h to give 5-(3-aminopropyl)-1H-imidazol-2(3H)-one as a yellow oil, which was used directly for the next step. The 5-(3-aminopropyl)-1H-imidazol-2(3H)-one obtained above (64.0 mg, 0.453 mmol, 1.0 equiv), 4,5-dibromo-2-(trichloroacetyl)pyrrole S12 (247.8 mg, 0.669 mmol, 1.5 equiv) was dissolved in anhydrous N,N-dimethylformamide (8 mL). Triethylamine (0.19 mL, 1.34 mmol, 3.0 equiv) was added and the solution was stirred at 60 °C under argon in dark for 3 h. The solvent was then removed and the residue was triturated with ether (3 ml×4). The solid was washed with HCl (0.1 N, 10 mL), water and dried under vacuum in the presence of phosphorus pentoxideto give 13 as off-white solid (159.8 mg, 41% over 4 steps): R f = 0.15 (10% methanol-methylene chloride); FTIR (neat, cm -1 ) 3401, 3307, 1996, 1681, 1643, 1531, 1416; 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.67 (s, 1H), 9.75 (s, 1H), 9.42 (s, 1H), 8.12 (t, J = 5.6 Hz, 1H), 6.91 (d, J = 2.7 Hz, 1H), 5.97 (s, 1H), 3.20 (dt, J = 6.8, 6.4 Hz, 2H), 2.24 (t, J = 7.3 Hz, 2H), 1.67 (tt, J = 7.3, 6.8 Hz, 2H); 13 C NMR (100 MHz, DMSO-d 6 ) δ 158. 9, 154.9, 128.2, 121.4, 112.4, 104.4, 103.7, 97.8, 38.0, 27.7, 22.6 (±)-Dibromophakellstatin. Imidazolinone 13 (50 mg, 0.128 mmol, 1.0 equiv) was suspended in 2,2,2-trifluoroethanol (5 mL) (sonicate the mixture to give fine suspension if necessary) and anhydrous sodium carbonate (136.4 mg, 1.28 mmol, 10 equiv), iodobenzene diacetate (41.1 mg, 0.128 mmol, 1.0 equiv) was added at 23 °C. The reaction mixture became clear after several min. After stirring for 1 h, sodium carbonate was filtered off and the filtrate was concentrated to nearly dryness. With stirring, HCl (0.1 N, 5 mL) was added dropwise to the resulting residue. After stirring for 10 min, the 9, 154.1, 125.4, 113.8, 105.6, 101.2, 79.0, 68.6, 44.2, 40.4, 18.9 
